Home›Neurology› Rasagiline and selegiline show comparable efficacy and safety in early Parkinson's disease
Rasagiline and selegiline show comparable efficacy and safety in early Parkinson's diseaseRasagiline and selegiline offer similar relief for early Parkinson's
Annals of medicinePublished August 20, 2026Study authors: Zhou Hanzong, Li Dandan, Yu Junxian, Gu Zheng, Wei HongtaoPubMed ↗DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider either rasagiline or selegiline for short-term symptom control, but note rasagiline's higher cost.
This meta-analysis, based on an indirect treatment comparison using placebo as a common anchor, evaluated rasagiline versus selegiline in patients with early-stage Parkinson's disease. The analysis focused on short-term symptomatic relief measured by UPDRS total scores, adverse event incidence, and cost-effectiveness. Clinical outcomes were assessed over 10 to 16 weeks, while the economic model extended to 2 years.
For symptomatic relief, the pooled effect size was -0.82 (95% CI [-2.08, 0.44], p = 0.203), indicating no statistically significant difference between the two drugs. Similarly, the risk of adverse events did not differ significantly (OR 0.83, 95% CI [0.50, 1.38], p = 0.475). These findings suggest comparable short-term efficacy and safety profiles.
Regarding cost-effectiveness, rasagiline was associated with an incremental cost-effectiveness ratio (ICER) of 1,951,505.55 Yuan/QALY, reflecting higher costs without additional benefit. The economic model was based on a 2-year Markov model from a Chinese healthcare-system perspective, which may limit generalizability to other settings.
The authors note the absence of direct head-to-head trials as a key limitation, and the economic conclusions are region-specific. The certainty of the evidence is moderate. For clinical practice, these results support that either drug may be a reasonable choice for short-term management, but cost considerations may favor selegiline.
How this fits prior evidence
This meta-analysis extends prior coverage on Parkinson's disease by comparing two commonly used MAO-B inhibitors, rasagiline and selegiline, in early-stage disease. It confirms the lack of significant difference in short-term efficacy and safety, aligning with the moderate certainty of prior evidence. It also addresses a gap by providing cost-effectiveness data, though from a Chinese perspective, which contrasts with the broader international focus of earlier findings on pain, tavapadon, GLP-1RAs, and institutionalisation risk.
Living with Parkinson's disease means managing daily symptoms that can affect movement and quality of life. For those in the early stages of the condition, doctors often look at options like rasagiline and selegiline to provide short-term relief. A recent review of data compared these two medications directly to see how they stack up against each other.
The findings show that both rasagiline and selegiline work about the same when it comes to improving symptoms. Patients taking either medication saw similar improvements in their overall scores. Additionally, the study found no significant difference in the risk of side effects between the two drugs, meaning both were equally well-tolerated by patients.
While they are equally effective for symptom management, there is a catch regarding cost. Because the analysis looked at economic models, it found that rasagiline was not considered cost-effective at its current price point compared to selegiline. It is important to note that this specific cost finding was based on a model from the Chinese healthcare system. Talk with your doctor to decide which option fits your personal needs and budget.
What this means for you:
Rasagiline and selegiline provide similar symptom relief and safety for early Parkinson's disease.
Common questions
Are there any differences in side effects between these two drugs?
No, the study found no statistically significant difference in the risk of adverse events between rasagiline and selegiline. Both medications were shown to have similar safety profiles for patients with early-stage Parkinson's disease.
Which medication is better for managing symptoms?
Both rasagiline and selegiline provide comparable short-term symptomatic relief. The data showed no statistically significant differences in the scores used to measure how well these drugs managed Parkinson's symptoms.
Is one of these medications more cost-effective?
While both are effective, rasagiline was not found to be cost-effective at its current pricing compared to selegiline. This specific finding was based on a two-year economic model from the Chinese healthcare system.
OBJECTIVE: Given the persistent absence of direct head-to-head trials, this study aimed to evaluate the comparative efficacy, safety, and cost-effectiveness of rasagiline versus selegiline as early-stage monotherapy for Parkinson's disease (PD), informing clinical selection and healthcare policies in China.
METHODS: A systematic search of PubMed, Embase, and the Cochrane Library identified randomized controlled trials (RCTs) up to April 2026. Focusing on short-term outcomes (10-16 weeks), an adjusted indirect treatment comparison (ITC) using placebo as a common anchor evaluated symptom improvement (UPDRS total scores) and adverse event (AE) incidence. For economic evaluation, a 2-year Markov model was constructed from a Chinese healthcare-system perspective. The incremental cost-effectiveness ratio (ICER) was calculated alongside robust sensitivity analyses.
RESULTS: Ten RCTs (rasagiline: 6; selegiline: 4) were included. The ITC revealed no statistically significant differences between rasagiline and selegiline in short-term symptomatic relief (Mean Difference = -0.82, 95% CI [-2.08, 0.44], = 0.203) or AE risk (Odds Ratio = 0.83, 95% CI [0.50, 1.38], = 0.475). The overall evidence certainty was rated as moderate. Economically, the base-case simulation indicated rasagiline yielded a marginal benefit of 0.0088 QALYs over selegiline but incurred an additional 17,111.10 Yuan. This resulted in an ICER of 1,951,505.55 Yuan/QALY, substantially exceeding the conventional willingness-to-pay threshold.
CONCLUSION: Supported by moderate-certainty evidence, rasagiline and selegiline provide comparable short-term efficacy and safety for early-stage PD monotherapy. However, at its current pricing, rasagiline is not cost-effective. Significant price reductions or definitive proof of long-term superiority are required to justify its economic value.
